Tenax Therapeutics, Inc. (TENX)
NASDAQ: TENX · Real-Time Price · USD
6.36
-0.13 (-1.98%)
Apr 1, 2025, 3:59 PM EDT - Market closed

Tenax Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Selling, General & Admin
6.795.015.686.385.31
Upgrade
Research & Development
12.713.235.3825.154.56
Upgrade
Operating Expenses
19.498.2311.0531.539.87
Upgrade
Operating Income
-19.49-8.23-11.05-31.53-9.87
Upgrade
Interest Expense
-0.02-0.02-0-0-0
Upgrade
Interest & Investment Income
1.910.48---
Upgrade
Other Non Operating Income (Expenses)
00.060.010.020.03
Upgrade
EBT Excluding Unusual Items
-17.6-7.71-11.05-31.51-9.84
Upgrade
Gain (Loss) on Sale of Investments
----0.01-0.01
Upgrade
Gain (Loss) on Sale of Assets
--0--
Upgrade
Other Unusual Items
----0.95-
Upgrade
Pretax Income
-17.6-7.71-11.05-32.47-9.85
Upgrade
Net Income
-17.6-7.71-11.05-32.47-9.85
Upgrade
Net Income to Common
-17.6-7.71-11.05-32.47-9.85
Upgrade
Shares Outstanding (Basic)
3000-
Upgrade
Shares Outstanding (Diluted)
3000-
Upgrade
Shares Change (YoY)
1276.92%1250.92%43.00%--
Upgrade
EPS (Basic)
-5.15-31.04-600.72-2525.03-
Upgrade
EPS (Diluted)
-5.15-31.04-600.72-2525.03-
Upgrade
Free Cash Flow
-14.81-5.9-11.39-10.86-9.28
Upgrade
Free Cash Flow Per Share
-4.33-23.76-619.37-844.53-
Upgrade
EBITDA
-19.49-8.23-11.05-31.52-9.86
Upgrade
D&A For EBITDA
0.010.010.0100
Upgrade
EBIT
-19.49-8.23-11.05-31.53-9.87
Upgrade
Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q